Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 4 of 4

Publication Record

Connections

Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma.
Lehner SG, Gould JE, Saad WE, Brown DB
(2005) AJR Am J Roentgenol 185: 1307-9
MeSH Terms: Carcinoma, Hepatocellular, Catheter Ablation, Humans, Liver Neoplasms, Male, Middle Aged, Tomography, X-Ray Computed, Tumor Lysis Syndrome, Ultrasonography
Added March 5, 2014
0 Communities
1 Members
0 Resources
9 MeSH Terms
Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system.
Lambright ES, Caparrelli DJ, Abbas AE, Toyoizumi T, Coukos G, Molnar-Kimber KL, Kaiser LR
(1999) Ann Thorac Surg 68: 1756-60; discussion 1761-2
MeSH Terms: Animals, Carcinoma, Lewis Lung, Disease Models, Animal, Genetic Therapy, Herpesvirus 1, Human, Mice, Mice, Inbred C57BL, Mice, SCID, Neoplasm Transplantation, Tumor Lysis Syndrome, Viruses
Show Abstract · Added March 5, 2014
BACKGROUND - Herpes simplex virus (HSV)-1716, a replication-restricted herpes simplex virus type 1, has shown efficacy as an oncolytic treatment for central nervous system tumors, breast cancer, ovarian cancer, and malignant mesothelioma. We evaluated the efficacy of HSV-1716 in a murine lung cancer model, Lewis lung carcinoma.
METHODS - Lewis lung carcinoma cells were infected with HSV-1716 and implanted in the flanks of mice at varying ratios of infected to uninfected cells. Tumor burden was assessed by measurement of the weight of the tumor nodule. The role of the immune system was examined by performing experiments in both immunocompetent and SCID mice. Tumors were implanted in the opposite flank to evaluate the vaccine effect.
RESULTS - In immunocompetent and SCID animals, ratio of 1:10 (infected-to-uninfected) cells completely prevented tumor formation and ratio of 1:100 suppressed tumor growth. Established tumors at a distant site in the groups receiving HSV-1716 infected cells showed no difference in size versus control, suggesting absence of a vaccine effect.
CONCLUSIONS - We conclude that HSV-1716 may provide a oncolytic therapy for lung cancer even in the absence of immune system induction and a "carrier" cell could potentially deliver this vector.
0 Communities
1 Members
0 Resources
11 MeSH Terms
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
Fassas AB, Desikan KR, Siegel D, Golper TA, Munshi NC, Barlogie B, Tricot G
(1999) Br J Haematol 105: 938-41
MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunoglobulin Light Chains, Kidney Diseases, Male, Middle Aged, Multiple Myeloma, Retrospective Studies, Risk Factors, Treatment Outcome, Tumor Lysis Syndrome
Show Abstract · Added August 7, 2015
Tumour lysis syndrome (TLS), because of its low proliferative activity, is thought to only rarely complicate the treatment of patients with multiple myeloma. However, as more aggressive therapeutic approaches are increasingly used in the management of this disease, it is conceivable that clinicians will encounter this complication more frequently. A retrospective analysis of > 800 patients with multiple myeloma treated at the University of Arkansas identified nine patients who developed a marked tumour lysis syndrome following intermediate- or high-dose chemotherapy. Evaluation of disease characteristics revealed association with high tumour mass, high proliferative activity, increased lactic dehydrogenase levels, plasmablastic morphology, and unfavourable cytogenetic abnormalities. Recognition of multiple myeloma patients at high risk for the development of tumour lysis syndrome and prompt intervention are required especially in the presence of abnormal baseline renal function frequently complicating the clinical course of these patients.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.
Hande KR, Garrow GC
(1993) Am J Med 94: 133-9
MeSH Terms: Acute Disease, Allopurinol, Antineoplastic Combined Chemotherapy Protocols, Blood Urea Nitrogen, Burkitt Lymphoma, Creatinine, Humans, Hyperkalemia, Hypocalcemia, L-Lactate Dehydrogenase, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Phosphates, Renal Insufficiency, Retrospective Studies, Risk Factors, Tumor Lysis Syndrome, Uric Acid
Show Abstract · Added March 5, 2014
PURPOSE - To identify patients with lymphoma at risk for tumor lysis after chemotherapy.
PATIENTS AND METHODS - The case records of 102 patients receiving combination chemotherapy for non-Hodgkin's lymphoma (intermediate to high-grade histology) were reviewed. Patients were considered to have "laboratory tumor lysis" if two of the following metabolic changes occurred within 4 days of treatment: a 25% increase in the serum phosphate, potassium, uric acid, or urea nitrogen concentrations, or a 25% decline in the serum calcium concentration. "Clinical tumor lysis" was defined as laboratory tumor lysis plus one of the following: a serum potassium level greater than 6 mmol/L, a creatinine level greater than 221 mumol/L, or a calcium level less than 1.5 mmol/L, the development of a life-threatening arrhythmia, or sudden death.
RESULTS - Laboratory tumor lysis occurred in 42% of patients and clinical tumor lysis in 6%. There was no statistical difference in the frequency of either tumor lysis syndrome among lymphoma subgroups. Clinical tumor lysis occurred more frequently in patients with pretreatment renal insufficiency (serum creatinine level greater than 132 mumol/L) than in patients with normal renal function (36% versus 2%; p = 0.01). The development of azotemia correlated with high pretreatment serum lactate dehydrogenase concentrations (p < 0.01; r2 = 0.11).
CONCLUSION - Clinically significant tumor lysis is a rare occurrence in patients with lymphoma when they are receiving allopurinol. However, tumor lysis can occur in patients with all types of moderate to high-grade non-Hodgkin's lymphoma. Patients with a high serum lactate dehydrogenase level or renal insufficiency are at increased risk for metabolic complications after chemotherapy and should be closely monitored.
0 Communities
1 Members
0 Resources
20 MeSH Terms